NCT06463171尚未招募2 期
Phase II Clinical Study of Almonertinib in Combination With Lastet in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR Mutations
Shanghai Pulmonary Hospital, Shanghai, China2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Progression-Free Survival
研究概览
简要总结
The goal of this clinical trial is to test in Locally Advanced or Metastatic Non-small Cell Lung Cancer patients with EGFR Mutations. The main question it aims to answer is:
Evaluation of the Efficacy and Safety of Aumolertinib in Combination with Lastet for the Treatment of EGFR-Mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer in First-line Therapy.
Participants will be treated with a combination of Aumolertinib and Lastet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Prior to the implementation of any trial-related procedures, written informed consent must be obtained.
- •Age ≥18 years.
- •Patients with locally advanced (Stage III B/III C), metastatic, or recurrent (Stage IV) non-small cell lung cancer (NSCLC) confirmed histologically or cytologically, who are ineligible for surgical intervention and cannot undergo curative radiochemotherapy, as per the 8th edition TNM staging classification of the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer.
- •Provide archived tumor tissue or tissue obtained from biopsy at screening for biomarker testing, including EGFR mutation status, etc.;
- •Presence of EGFR positive mutation;
- •Investigator confirmation of at least one measurable lesion according to RECIST 1.1 criteria.
- •Patients who have previously received platinum-containing adjuvant chemotherapy/radiotherapy, neoadjuvant chemotherapy/radiotherapy, or radical radiochemotherapy for advanced disease, with disease progression occurring >6 months after the last treatment, may participate in this study;
- •Expected life expectancy ≥3 months.
- •ECOG PS 0-
- •Adequate hematologic function, defined as an absolute neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90g/L (without a history of blood transfusion in the past 7 days).
- •Adequate liver function, defined as total bilirubin level ≤1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤2.5 times ULN for all patients, or for patients with liver metastasis, AST and ALT levels ≤5 times ULN.
- •Adequate renal function, defined as serum creatinine ≤1.5 times ULN.
- •Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; if a subject is on anticoagulant therapy, INR/PT should be within the therapeutic range set by the anticoagulant.
- •Women of childbearing potential must undergo a pregnancy test within 7 days prior to the start of treatment, with negative results; and reliable contraception methods (such as intrauterine devices, oral contraceptives, and condoms) should be used during the trial and for 30 days after the end of the trial. Men of childbearing potential should use condoms for contraception during the trial and for 30 days after the end of the trial.
- •Willingness to comply with regular follow-up visits and adhere to trial requirements.
排除标准
- •Currently participating in an interventional clinical study treatment;
- •Have previously received anti-EGFR treatment;
- •Received traditional Chinese medicine with antitumor indications or immunomodulatory drugs (such as thymosin, interferon, interleukin, etc.) within 2 weeks before the first dose;
- •Have a history of allergic reactions to any of the study drug components.
- •Have active hemoptysis (more than half a teaspoon), active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal metastasis;
- •Have tumor compression of surrounding vital organs (such as the esophagus) with accompanying related symptoms, compression of the superior vena cava, or invasion of major mediastinal vessels, the heart, etc.;
- •Known to have brain metastases. Patients judged by the investigator to be asymptomatic or have stable brain metastases may be enrolled;
- •Have active systemic infections, including tuberculosis (clinical diagnosis including medical history, physical examination, imaging findings, and TB testing according to local medical routines), hepatitis B (known to be HBV surface antigen (HBsAg) positive, with HBV DNA ≥1000cps/ml or the lower limit of the reference value), hepatitis C, or human immunodeficiency virus (HIV antibody positive);
- •Known to have mental illness or substance abuse that may affect compliance with trial requirements;
- •Recently treated with a full dose of oral or non-oral anticoagulants or thrombolytics. Prophylactic use of anticoagulants is allowed.
- •Have a medical history, disease, treatment, or laboratory abnormality that may interfere with the trial results or prevent the subject from participating in the study throughout, or the investigator considers participation in the study not to be in the best interest of the subject.
研究组 & 干预措施
combination therapy
Experimental
Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.
Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.
干预措施: Almonertinib (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: up to 24 months
PFS is defined as the period from the start of treatment until the disease progresses or the patient dies from any cause, whichever came first, assessed up to 24 months
次要结局
- Overall Survival(up to 24 months)
- Disease Control Rate(24 months)
- Duration of Response(24 months)
- Objective Response Rate(24 months)
研究者
Chunxia Su
Director of the Clinical Research Center
Shanghai Pulmonary Hospital, Shanghai, China
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Osimertinib In EGFR Mutant Lung CancerCarcinoma, Non-Small-Cell LungNCT03586453Dana-Farber Cancer Institute30
终止
2 期
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaALK-positive Non-small Cell Lung CancerNCT02513667University of Texas Southwestern Medical Center14
招募中
2 期
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeAdvanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7NCT03191149National Cancer Institute (NCI)46
已完成
不适用
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be ControlledNon-Small Cell Lung CarcinomaNCT06282991Pfizer73
尚未招募
2 期
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesAdenocarcinoma of Lung Metastatic to BrainNCT06483672Cancer Institute and Hospital, Chinese Academy of Medical Sciences27